Clarification of how HIV-1 DNA and protein immunizations may be better used to obtain HIV-1-specific mucosal and systemic immunity (Q36780136)

16 August 2017

1 reference

title

Clarification of how HIV-1 DNA and protein immunizations may be better used to obtain HIV-1-specific mucosal and systemic immunity (English)

1 reference

16 August 2017

0 references

Jorma Hinkula

1

1 reference

16 August 2017

1 April 2007

1 reference

Expert Review of Vaccines

16 August 2017

1 reference

16 August 2017

6

1 reference

16 August 2017

2

1 reference

16 August 2017

203-212

1 reference

Poliovirus vaccine strains as mucosal vaccine vectors and their potential use to develop an AIDS vaccine.

16 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

Protection against simian immunodeficiency virus vaginal challenge by using Sabin poliovirus vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

HIV-1 vaccine-induced immune responses which correlate with protection from SHIV infection: compiled preclinical efficacy data from trials with ten different HIV-1 vaccine candidates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

New insights into HIV-1 specific cytotoxic T-lymphocyte responses in exposed, persistently seronegative Kenyan sex workers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

Role of secretory antibodies in the defence against infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

Enhanced cellular immunity and systemic control of SHIV infection by combined parenteral and mucosal administration of a DNA prime MVA boost vaccine regimen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

Sustained conservation of CD4+ T cells in multiprotein triple modality-immunized rhesus macaques after intrarectal challenge with simian immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

Controlling HIV pathogenesis: the role of the noncytotoxic anti-HIV response of CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

HIV-1-specific mucosal CD8+ lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

The role of gammadelta T cells in generating antiviral factors and beta-chemokines in protection against mucosal simian immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

A critical role for neutralizing-antibody-producing B cells, CD4(+) T cells, and interferons in persistent and acute infections of mice with lymphocytic choriomeningitis virus: implications for adoptive immunotherapy of virus carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

Nasal and vaginal vaccinations have differential effects on antibody responses in vaginal and cervical secretions in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

Mucosal B cells: phenotypic characteristics, transcriptional regulation, and homing properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

Mucosal immunity and vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

Women with cervicovaginal antibody-dependent cell-mediated cytotoxicity have lower genital HIV-1 RNA loads

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

NALT- versus Peyer's-patch-mediated mucosal immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

Comparison of different routes of vaccination for eliciting antibody responses in the human stomach

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

Local and systemic immune responses to rectal administration of recombinant cholera toxin B subunit in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

The induction of systemic and mucosal immune responses to antigen-adjuvant compositions administered into the skin: alterations in the migratory properties of dendritic cells appears to be important for stimulating mucosal immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

Overcoming immunity to a viral vaccine by DNA priming before vector boosting

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

HIV vaccine design: insights from live attenuated SIV vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

Antibody vs. HIV in a clash of evolutionary titans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

Impact of vaccine-induced mucosal high-avidity CD8+ CTLs in delay of AIDS viral dissemination from mucosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

A nonsense mutation (428G-->A) in the fucosyltransferase FUT2 gene affects the progression of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

Secretory IgA specific for a conserved epitope on gp41 envelope glycoprotein inhibits epithelial transcytosis of HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

A mucosally targeted subunit vaccine candidate eliciting HIV-1 transcytosis-blocking Abs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

HIV vaccine design and the neutralizing antibody problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

HIV vaccines: brief review and discussion of future directions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

Therapeutic vaccination against HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

Human clinical trials of plasmid DNA vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

Approaches to improve engineered vaccines for human immunodeficiency virus and other viruses that cause chronic infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

Mucosal and systemic anti-HIV responses in rhesus macaques following combinations of intranasal and parenteral immunizations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

Immunobiology of mucosal HIV infection and the basis for development of a new generation of mucosal AIDS vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

Genetic immunization with multiple HIV-1 genes provides protection against HIV-1/MuLV pseudovirus challenge in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

Intranasal HIV-1-gp160-DNA/gp41 peptide prime-boost immunization regimen in mice results in long-term HIV-1 neutralizing humoral mucosal and systemic immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

Induction of HIV-1-specific immunity after vaccination with apoptotic HIV-1/murine leukemia virus-infected cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

Mechanisms of stimulation of the immune response by aluminum adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

CpG motifs in bacterial DNA trigger direct B-cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

CD8+ T-cell-mediated cross-clade protection in the genital tract following intranasal immunization with inactivated human immunodeficiency virus antigen plus CpG oligodeoxynucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

Medicinal chemistry and therapeutic potential of CpG DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

Immunomodulators and delivery systems for vaccination by mucosal routes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

Vaccine presentations and delivery technologies--what does the future hold?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

Topical delivery of imiquimod to a mouse model as a novel adjuvant for human immunodeficiency virus (HIV) DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

Induction of mucosal protection against primary, heterologous simian immunodeficiency virus by a DNA vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

A dose sparing effect by plasmid encoded IL-12 adjuvant on a SIVgag-plasmid DNA vaccine in rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

Control of simian/human immunodeficiency virus viremia and disease progression after IL-2-augmented DNA-modified vaccinia virus Ankara nasal vaccination in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

Mucosal vaccines: the promise and the challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

Current evidence and future directions for targeting HIV entry: therapeutic and prophylactic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

Enhanced breadth of CD4 T-cell immunity by DNA prime and adenovirus boost immunization to human immunodeficiency virus Env and Gag immunogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

Strategies for designing and optimizing new generation vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

Mucosally-administered human-simian immunodeficiency virus DNA and fowlpoxvirus-based recombinant vaccines reduce acute phase viral replication in macaques following vaginal challenge with CCR5-tropic SHIVSF162P3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag c

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of beta-chemokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

Multi-subtype gp160 DNA immunization induces broadly neutralizing anti-HIV antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

Effective induction of simian immunodeficiency virus-specific systemic and mucosal immune responses in primates by vaccination with proviral DNA producing intact but noninfectious virions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

Protective efficacy of a multicomponent vector vaccine in cynomolgus monkeys after intrarectal simian immunodeficiency virus challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

DNA mucosal HIV vaccine in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

Serum IgA of HIV-exposed uninfected individuals inhibit HIV through recognition of a region within the alpha-helix of gp41.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

Comparative evaluation of three different intramuscular delivery methods for DNA immunization in a nonhuman primate animal model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

Cervicovaginal secretory antibodies to human immunodeficiency virus type 1 (HIV-1) that block viral transcytosis through tight epithelial barriers in highly exposed HIV-1-seronegative African women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

Sexual Transmission and Propagation of SIV and HIV in Resting and Activated CD4+ T Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

Functional HIV-1 specific IgA antibodies in HIV-1 exposed, persistently IgG seronegative female sex workers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

European Union and EDCTP strategy in the global context: Recommendations for preventive HIV/AIDS vaccines research

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.203

21 January 2018

Identifiers

DOI

10.1586/14760584.6.2.203

1 reference

16 August 2017

1 reference

PubMed ID

17408370